Sionna Therapeutics’ Post

Looking at the 20 top pharma companies by market cap reveals some clear trends, yet others are more subtle: #Medicalscienceliaison #MedicalAffairs #PharamceuticalIndustry While Eli Lilly and Novo Nordisk have long been in the top 20, only in the last ~2 years have they broken into the top tier, thanks to their GLP-1s. Lilly is now amongst the 10 most valuable companies in the world, across all industries. While weight loss drugs have gotten the headlines, others delivered impressive gains over the last 3 years as well: AstraZeneca increased its value by ~50%, largely thanks to its strong oncology portfolio, with blockbusters like Tagrisso that delivered ~$6B in sales in FY2023. Meanwhile, Regeneron and Vertex almost doubled their value, driven by Dupixent/Eylea and Trikafta respectively. One of the most surprising results is from AbbVie, which increased its market cap from ~$200B to ~$300B in the last 3 years, despite the fact its best-seller Humira began to face competition during that time. 👩⚕️ 💊 Have you joined the MSL and medical affairs linkedin community yet? Over 18.000 med. affairs professionals across the globe sharing jobs, tips and actively networking.   🛎 👉 This is the link: https://lnkd.in/gZ_mBprH

Looking at the 20 top pharma companies by market cap reveals some clear trends, yet others are more subtle: #Medicalscienceliaison #MedicalAffairs #PharamceuticalIndustry While Eli Lilly and Novo Nordisk have long been in the top 20, only in the last ~2 years have they broken into the top tier, thanks to their GLP-1s. Lilly is now amongst the 10 most valuable companies in the world, across all industries. While weight loss drugs have gotten the headlines, others delivered impressive gains over the last 3 years as well: AstraZeneca increased its value by ~50%, largely thanks to its strong oncology portfolio, with blockbusters like Tagrisso that delivered ~$6B in sales in FY2023. Meanwhile, Regeneron and Vertex almost doubled their value, driven by Dupixent/Eylea and Trikafta respectively. One of the most surprising results is from AbbVie, which increased its market cap from ~$200B to ~$300B in the last 3 years, despite the fact its best-seller Humira began to face competition during that time. 👩⚕️ 💊 Have you joined the MSL and medical affairs linkedin community yet? Over 18.000 med. affairs professionals across the globe sharing jobs, tips and actively networking.   🛎 👉 This is the link: https://lnkd.in/eKQNrKM

I've seen firsthand the struggles patients face in accessing specialty medications - from friends, family, and even my own doctors. I'm incredibly passionate about our mission to make it easier and faster for Americans to get on life-saving therapies & this funding will help us make an even greater impact. If you work in #MarketAccess #PatientAdvocacy or #BrandMarketing and are interested in how Samacare can decrease time to approval & administrative burden, let's connect! #SamaCare #SeriesB #Funding #Healthcare #PatientAccess #SpecialtyMedications

What is needed to improve the transfer of ideas from bench to bedside, to provide more effective treatments for "patients" in need? How can stakeholders in the healthcare ecosystem—including patient groups, scientists, investors, the pharmaceutical industry and med-tech innovators—collaborate to improve and accelerate processes in the search for better outcomes, and even cures? From bench to bedside—accelerating progress in healthcare innovations | Feb 7th 2024 | https://lnkd.in/dzpTZSwm Parkinson's Europe

**Exciting Breakthrough in Pharma! 🌟** The pharmaceutical landscape is buzzing with innovation as Vertex Pharmaceuticals recently announced a game-changing development! Vertex's groundbreaking new therapy for cystic fibrosis has received FDA approval, marking a significant leap forward in treating this debilitating disease. This new treatment, Trikafta, targets the root cause of cystic fibrosis and promises to enhance the quality of life for thousands of patients. But that's not all! The industry is also witnessing a surge in AI-driven drug discovery, with companies like Insilico Medicine leading the charge. By leveraging cutting-edge artificial intelligence, Insilico has accelerated the drug development process, bringing new hope to patients with unmet medical needs. These advancements highlight the transformative potential of technology and innovation in healthcare. It's an inspiring time to be in the pharma industry, where every new discovery brings us closer to a healthier future. Let's celebrate these milestones and continue pushing the boundaries of what's possible in medicine! 💊🔬 Vinod K Sharma,Ph.D #PharmaNews #Innovation #Healthcare #CysticFibrosis #AI #DrugDiscovery #VertexPharmaceuticals #InsilicoMedicine #FDAApproval

TME Pharma published the Half-Year Report 2023 highlighting the financial results and latest clinical updates in the lead #NOXA12 program in #glioblastoma. Read the full PR:https://is.gd/YZcy9K

In the current issue of the BPCC's Contact Magazine Online Jarek Agatowski from AstraZeneca Pharma Poland says that AI has become a foundation in the activity of innovative pharma companies. A typical prescription drug development cycle takes 10-15 years and more than $2 billion investment per one new medicine. Now, AI is accelerating the drug discovery process, and reducing clinical trial costs. Poland also plays a vital role here. https://lnkd.in/dV5JezVd Maja Messyasz Agata Qanadilo #contactonline #AI #digitalisation #IT #pharmacy #pharma #medicine #Healthcare #clinicaltrials

MARKET ACCESS SURVEY: 47% of payers, IDNs, and other stakeholders plan to execute a prescription digital therapeutics strategy by 2025, according to our Second Annual Market Access Survey. - 40% say they will execute #AI plans by 2025 for administrative and manual functions, including streamlining prior authorization. “Organizations desire additional clarity regarding the value of prescription therapeutics and reimbursement,” says our colleague Tony Gibson. “CMS and FDA activity in this area will also spur payer planning in this area.” #marketaccess #pharma #biotech

#Drug_Device_Combination_Products Market Insights, Trends & Future Development Status Recorded during 2023-2032 >> https://lnkd.in/dCZJhjCN #Drug #device combination #products are #medical products that #combine a drug or #biologic substance with a medical device to deliver #therapeutic benefits or perform specific #treatment functions. Abbott, AbbVie., Alcon., Bausch Health Companies Inc., Baxter International Inc., Bayer, Becton, Dickinson and Company, Boston Scientific, GlaxoSmithKline Consumer Healthcare, L.P., Johnson & Johnson, Kaléo., Medtronic, Novartis, Sinomed, Smith+Nephew, Teleflex, Teva Pharmaceuticals #treatment #surgical #disorders #healthcare #medical #drugdevice #combinationproducts #biologic

When patients can communicate their symptoms, health data, and insights seamlessly with their healthcare provider, outcomes improve. Learn how Digital Therapeutics are transforming the healthcare landscape and how biopharmaceutical companies can leverage these innovations to become more patient-centric.  https://bit.ly/3PeMM1T #DigitalTherapeutics #DTx #AvalereHealth #PatientCentricity#DigitalHealth